Native Greens Launches Updated Website Section Featuring Daily Superfood Blend for Adult Wellness Support
Updated Product Page Highlights Organic Superfood Powder with 21 Plant-Based Ingredients for Digestive, Immune, and Energy Support
San Francisco, June 19, 2025 (GLOBE NEWSWIRE) --
Native Greens, a U.S.-based wellness brand focused on natural daily health support, has announced a new update to its official product website. The revised online section now features detailed product information, ingredient transparency, usage guidance, and direct ordering options for the company's popular superfood supplement blend.
The update reflects Native Greens' commitment to making wellness support easier and more accessible for adults seeking convenient, plant-based solutions. The refreshed web experience includes a streamlined layout, expanded FAQs, and clearer purchasing pathways for new and returning customers.
Website Update Offers Enhanced Navigation and Education
The digital refresh, introduced in June 2025, was developed to help health-conscious consumers quickly access the most relevant product information. Visitors can now explore Native Greens' intended uses, ingredient sourcing, quality standards, and customer satisfaction policies in greater detail.
The platform update also highlights the brand's continued emphasis on transparency, providing clear descriptions of what the formula contains and how it's intended to integrate into everyday routines.
What Is Native Greens?
Native Greens is a daily powdered superfood blend created for adults looking to supplement their diets with nutrient-dense, organic plant compounds. While not intended to diagnose or treat any medical condition, the formula is positioned as a food-based option to support general wellness when used consistently as part of a healthy lifestyle.
Each serving mixes easily with water or smoothies, offering a quick and flexible addition to morning or midday routines.
Ingredients and Intended Use
According to the official product page (https://nativepath.com/products/native-greens), the formula features 21 certified organic ingredients, including:
Leafy Greens & Grasses: Spinach, kale, broccoli, wheatgrass, barley grass, alfalfa
Algae & Marine Greens: Spirulina, chlorella, kelp
Root & Fruit Powders: Beetroot, turmeric, ginger, blueberry, pomegranate, acai, coconut water
Botanicals & Herbal Support: Astragalus, parsley, rosemary, spearmint, chia, apple fiber
These ingredients were selected to align with common adult wellness goals such as energy maintenance, digestion support, and antioxidant intake. Native Greens is dairy-free, gluten-free, soy-free, non-GMO, and contains no added sugars, artificial sweeteners, or nightshades.
Quality Assurance and Customer Satisfaction
Native Greens is manufactured in a cGMP-certified facility in the United States and undergoes third-party testing. Each batch is accompanied by a Certificate of Analysis (COA) to validate product integrity and safety. These details are now highlighted on the updated product page to help customers make informed choices.
To further support customer confidence, the brand offers a 365-day money-back guarantee. This satisfaction policy allows first-time buyers to try the product risk-free and return it if not satisfied.
Purchasing and Availability
Native Greens is available for purchase exclusively through the company's official website. The updated storefront now offers:
Tiered pricing based on volume
Secure checkout and encrypted transactions
Clear return instructions and customer support access
The supplement is currently available for U.S. customers, with potential expansion based on demand.
Wellness Support Made Simple
The updated website underscores the company's belief that health-supportive habits should be simple, flexible, and sustainable. Native Greens is designed to fit seamlessly into modern lifestyles, requiring minimal prep time and no restrictive diet changes.
Future updates are expected to include additional educational resources on wellness habits and nutrition, building on the company's effort to create an informative and supportive experience for health-conscious adults.
About Native Greens
Native Greens is a wellness brand based in the United States, focused on providing clean, easy-to-use dietary supplements that promote daily health support. Through simple formulations and transparent product labeling, the company empowers adults to maintain consistent wellness habits backed by ingredient quality and manufacturing integrity.
To learn more, visit: https://nativepath.com/products/native-greens
Contact
Email: info@nativegreens.com
Website: https://nativepath.com/products/native-greens
Disclaimer
This press release is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. Native Greens is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always consult a qualified healthcare provider before starting any new dietary supplement, especially if pregnant, nursing, or taking prescription medications.
CONTACT: Email: info@nativegreens.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating, and relapsing rare skin disease affecting approximately 27,000 adults in the US whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the US to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly people Paris and Tarrytown, NY, June 20, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). BP primarily affects elderly patients, and is characterized by intense itch, painful blisters, and lesions, as well as reddening of the skin. It can be chronic and relapsing with underlying type 2 inflammation. The blisters and rash can form over much of the body and cause the skin to bleed and break down, resulting in patients being more prone to infection and affecting their daily functioning. Available treatment options are limited and can add to overall disease burden by suppressing a patient's immune system. Executive Director, International Pemphigus and Pemphigoid Foundation 'People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden. The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone.' Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi 'Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with the debilitating impact of blisters and lesions, and potentially co-morbid conditions. By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve sustained remission and reduce itch. This approval in the US is important for the thousands of patients living with bullous pemphigoid, and we look forward to working with regulators around the world to bring this innovative medicine to more patients in need.' The FDA approval is based on data from the pivotal ADEPT phase 2/3 study that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP. Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. During the FDA review, the analyses were updated; the FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are: 18.3% of patients experienced sustained disease remission compared to 6.1% (12.2% difference; 95% confidence interval: -0.8% to 26.1%), the primary endpoint 38.3% of patients achieved clinically meaningful itch reduction compared to 10.5% Median cumulative OCS dose was 2.8 grams compared to 4.1 grams In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis. Additionally, one case of acute generalized exanthematous pustulosis was reported in one patient treated with Dupixent and zero patients treated with placebo. Board co-Chair, President, and Chief Scientific Officer at Regeneron 'This approval extends the remarkable ability of Dupixent to transform treatment paradigms for people living with a variety of diseases with underlying type 2 inflammation, from common conditions like asthma and atopic dermatitis, to rarer ones such as eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid. Dupixent has shown the potential to improve the most challenging effects of bullous pemphigoid, while helping some patients achieve sustained disease remission and decreased oral corticosteroid use. Additionally, this approval further reinforces the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and across dermatological, respiratory, and gastrointestinal diseases.' The FDA evaluated Dupixent under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions. Dupixent was previously granted orphan drug designation by the FDA for BP, which applies to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the US. Additional regulatory applications are also under review around the world, including in the EU, Japan, and China. About the Dupixent BP pivotal studyADEPT was a randomized, phase 2/3, double-blind, placebo-controlled study evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP for a 52-week treatment period. After randomization, patients received Dupixent or placebo every two weeks after an initial loading dose, along with OCS treatment. During treatment, OCS taper was initiated after patients experienced two weeks of sustained control of disease activity. OCS tapering could start between four to six weeks after randomization and was continued if disease control was maintained, with the intent of completion by 16 weeks. After OCS tapering, patients were only treated with Dupixent or placebo for at least 20 weeks (rescue treatment could be used if required). The primary endpoint evaluated the proportion of patients achieving sustained disease remission at 36 weeks. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by 16 weeks without relapse after completion of the OCS taper and no rescue therapy use during the 36-week treatment period. Relapse was defined as appearance of ≥3 new lesions a month or ≥1 large lesion or urticarial plaque (>10 cm in diameter) that did not heal within a week. Rescue therapy could include treatment with high-potency topical corticosteroids, OCS (including increase of OCS dose during the taper or re-initiation of OCS after completion of the OCS taper), or systemic non-steroidal immunosuppressive medications, or immunomodulating biologics. Select secondary endpoints evaluated at 36 weeks included: Proportion of patients with ≥4-point reduction in Peak Pruritus Numerical Rating Scale (scale 0-10) Total cumulative OCS dose About DupixentDupixent (dupilumab) is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with BP, Dupixent 300 mg is administered every other week after an initial loading dose, and in combination with a tapering course of oral corticosteroids. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, and BP in different age populations. More than one million patients are being treated with Dupixent globally. Dupilumab development programDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Sanofi Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Sanofi Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Regeneron Media RelationsAnna Hodge | +1 914-255-6475| Regeneron Investor RelationsMark Hudson | +1 914-847-3482 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of bullous pemphigoid as discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( and its LinkedIn page ( Press_ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Dieux Cofounders Launch Sun-Screener, a Tool Meant to Demystify SPF Filters for the Masses
Dieux cofounders Charlotte Palermino and Joyce de Lemos are looking to tackle SPF misinformation. The duo are launching a virtual tool, called Sun-Screener, which allows users to copy-paste the ingredient list of an SPF product in order to receive confirmation of its efficacy, plus breakdowns of active UV filters in the formula, how they each work, and in which regions they are approved for use. More from WWD Sesame Oil Skin Care: The Secret to Hydrated Skin or a Recipe for Clogged Pores? Clinique Doubles Down on Growth Strategy With More Launches, First TV Ad in a Decade Melanie Grant Partners With Violet Grey for New York Studio Opening The launch comes at a time when the sun care market — propelled by TikTok, the virality of Korean and Australian SPF brands around the world, and proliferating launches — is booming. But as the category has grown so, too, has misinformation surrounding it. 'We want to empower people with the information to make their own choices in an unbiased way — for us, that looks like stating the facts as they are, and making them easily accessible,' said de Lemos, who is also Dieux's cosmetic chemist. In recent months a movement toward beef tallow as an SPF alternative has gained momentum online, while influencer Nara Smith also took to TikTok to share how she makes her sunscreen from scratch, sparking a conversation about the viability of homemade SPF (which was quickly denounced by dermatologists). In addition, usage of product-scanning apps like Yuka, which designate ingredients as 'high-risk' or 'risk-free' without taking into account ingredient quantity or form of delivery — which are often key to determining ingredient safety — is soaring. 'We want to get people to wear sunscreen, but also to educate them in a nonjudgmental way, where we're not saying something is 'good' or something is 'bad' — that creates fear, not education,' said Palermino, who is known for creating content that makes skin care knowledge accessible to her 700,000-plus collective social media followers. Sun-Screener, developed and peer-reviewed alongside cosmetic chemists Rebecca Perry and Ava Perkins, briefs users on more than 35 different UV filters — from mineral filters titanium dioxide and zinc oxide to chemical filters like avobenzone, octocrylene and more. The brand will also build out a blog component addressing common SPF-related questions tied to the tool, which is accessible via Dieux's own direct-to-consumer site. 'The fun thing about Sun-Screener is that there's no 'bad' answer: it's either, good news — your sunscreen has sunscreen in it — you're fine! Or, we need more information,' said Palermino. Eventually, the tool could involve a feature enabling users to contact their representatives to request action regarding long-stalled FDA approval of newer, more sophisticated chemical SPF filters, many of which are available in other countries, hence the popularity of international SPF brands. 'We want to create a zero-fear environment to help people understand what's in their products, in a way where it's clear that sunscreen is good,' Palermino said. Best of WWD Sesame Oil Skin Care: The Secret to Hydrated Skin or a Recipe for Clogged Pores? How Grooming Is Introducing Men to Self-care and Redefining Masculinity Clean Beauty Brand Ignae Makes Big U.S. Push With a New Look
Health Line
an hour ago
- Health Line
14 Healthy Foods That Are High in Potassium
Many fruits and vegetables are high in potassium. This can include beans and sweet potatoes. Potassium is an essential mineral that the body requires for a variety of processes. Since the body can't produce potassium, it has to come from food. However, most Americans don't get enough potassium from their diets. This is mainly due to a lack of fruits and vegetables in the typical Western diet. In the United States, it's recommended that healthy adults consume 4,700 mg daily. Getting enough dietary potassium is essential for bone and heart health. It's vital for people with high blood pressure, as it may decrease the risk of heart disease and stroke. This article lists 14 foods that are highest in potassium. White beans Beans and lentils are both good sources of potassium. White beans are one of the best sources of potassium, with 421 mg of potassium in 1/2 cup (130 grams). White beans contain reasonable amounts of calcium and iron. Additionally, 1/2 cup of white beans provides 4.9 grams of fiber, which is 18% of your daily requirement. They're also an excellent source of plant-based protein. The beans' high fiber and antioxidant content can help decrease inflammation, improve colon health, and reduce the risk of heart disease and diabetes. A recent meta-analysis showed a significant reduction in stroke risk with a higher potassium intake in the diet. Potatoes and sweet potatoes White potatoes are one of the best food sources of potassium available. A large baked potato (299 grams) provides 1,600 mg. Since potassium is found in both the flesh and skin of a potato, it's most beneficial to consume them washed and unpeeled. Another starchy tuber rich in potassium is baked sweet potatoes. One of these large vegetables (235 grams) contains 1,110 mg. But potatoes aren't just good sources of potassium. They also contain vitamins A, C, B6, and manganese. Beets Beets, a root vegetable with a naturally sweet flavor, are available in various colors, such as deep red, purple, and white. A 1/2 cup (85 grams) of sliced and boiled beets contains 259 mg of potassium. Beets are also rich in folate and manganese. The pigment that gives beets their rich color acts as an antioxidant, which may help fight oxidative damage and inflammation. Beets are also high in nitrates, which may benefit blood vessel function, high blood pressure, and exercise performance. Beets' potassium content may also help improve blood vessel function and decrease the risk of heart disease. Spinach Spinach is a highly nutritious vegetable. Cooked spinach is a great option for those wanting to increase their potassium intake. It contains 839 mg of potassium per cup. It also provides 104% of the DV for vitamin A, over 7 times the DV for vitamin K, almost 19% of the DV for calcium, and around 73% of the DV for manganese. These nutrients are important for metabolism, vision health, bone health, and the immune system. Dark leafy green vegetables like spinach also contain antioxidants, including flavonoids, which help protect against cellular damage. Swiss chard Swiss chard is a leafy green vegetable that's highly nutritious. It's packed with nutrients. One cup (175 grams) of cooked Swiss chard contains 961 mg of potassium. It also contains vitamins A, K, and C, iron, plus magnesium, manganese, and fiber. Like spinach, kale, and other leafy green vegetables, Swiss chard also contains healthy plant compounds that act as antioxidants to help protect your cells. Tomatoes and tomato sauce Tomatoes and tomato products, such as tomato sauce, are full of potassium. One cup (245 grams) of tomato sauce contains 728 mg of potassium. Tomatoes are also rich in other minerals, like manganese, and vitamins, including vitamins A, C, E, and B6. What's more, tomatoes contain beneficial plant compounds like lycopene, which may help fight inflammation and reduce prostate cancer risk. A small study of people with metabolic syndrome who received tomato juice four times a week for 2 months saw significant improvement in inflammation, blood vessel dysfunction, and insulin resistance. A recent review of studies found that lycopene provided significant antioxidant and anti-inflammatory benefits and lowered the components of metabolic syndrome, including high blood pressure, obesity, and insulin resistance, in both animal and human subjects. The participants also experienced a decrease in LDL (bad) cholesterol and a slight increase in HDL (good) cholesterol. The beneficial effects of potassium and lycopene on heart disease risk factors make tomatoes an excellent choice for heart health. Oranges and orange juice Citrus fruits like oranges are well known for being high in vitamin C, but they're also a good source of potassium. One cup (248 grams) of orange juice provides 496 mg of potassium. It's also rich in folate, vitamin A, thiamine, and antioxidants. Observational studies have found that people who regularly consume orange juice have a higher intake of vitamin C, potassium, calcium, and vitamin D, and are also more likely to have a lower BMI. Additionally, the high level of antioxidants in oranges and their juice may help improve the body's ability to fight free radicals, inflammation, and heart disease. Furthermore, consuming orange juice fortified with calcium and vitamin D may help improve bone health, especially since a high potassium intake may also benefit bone health. But remember that orange juice is higher in sugar and provides less fiber than the whole fruit. Thus, it's best to focus on eating the fruit rather than drinking juice as a source of vitamins and minerals. If you choose to drink orange juice, ensure it's 100% juice without added sugars. Bananas Bananas are known to be a good source of potassium. In fact, one banana has 451 mg of potassium. This tasty fruit is also rich in vitamin C, vitamin B6, magnesium, fiber, and antioxidants. While ripe bananas tend to be high in sugar, green bananas are lower in sugar and higher in resistant starch, which may help manage blood sugar and improve gut health. Green bananas and green banana powder may help enhance fullness, improve constipation and diarrhea, and help some people lose weight. The banana's convenient, natural packaging makes it an easy and nutritious way to increase your potassium intake on the go. Avocados Avocados are incredibly nutritious, tasty, and unique. They're high in heart-healthy monounsaturated fats and rich in fiber, antioxidants, vitamins C, K, B6, folate, and pantothenic acid. Avocados are also a good source of potassium. One cup (150 grams) of whole avocado provides 728 mg of potassium. The high content of antioxidants, healthy fats, and fiber in avocados is most likely responsible for their positive health effects. Studies have shown that avocados may benefit heart health, weight management, and metabolic syndrome. A 2017 study associates eating avocados with better diet quality, lower BMI, body weight, waist circumference, and a significantly lower risk of metabolic syndrome. However, more recent studies have found that avocados may not necessarily be linked with lower body weight and instead have a neutral effect on weight, or they may only affect particular populations. In one study, avocados were found to lower weight gain in female participants but not male ones. The rich potassium content of avocados and their other healthy properties make them an easy choice for helping meet your nutrient needs. Yogurt Yogurt is an excellent source of calcium, riboflavin, and potassium. One cup (245 grams) of this creamy treat provides you with 380 mg of potassium. Because yogurt is a fermented food, it also contains bacteria that may benefit gut health. Some evidence also suggests that yogurt may be beneficial for managing appetite or weight maintenance. This is likely related more to its high protein than its probiotic content. When buying yogurt, aim for a plain variety, as fruit-flavored yogurts tend to have lots of added sugar. Greek yogurt may be a better option due to its higher protein content. If you find plain yogurt is too tart, sweeten it with fresh fruit, nuts, a little honey, or maple syrup. Clams Clams are an excellent source of potassium. A 3-ounce serving (85 grams) provides 534 mg. Clams are also extremely rich in other nutrients. One serving offers 99% of the DV for selenium and surpasses the DV for vitamin B12. They're also a great source of protein and high in healthy omega-3 fats, which are associated with various health benefits, including reducing inflammation and other risk factors associated with related diseases. Salmon Salmon is a highly nutritious food. It's packed with high quality protein, healthy omega-3 fats, and many vitamins and minerals, including potassium. Half of a filet of salmon (178 grams) provides 684 mg of potassium. A diet rich in fatty fish has also been linked with various health benefits, most notably a decreased risk of heart disease. In fact, a meta-analysis of 18 studies found that eating 2-3 150 g portions of fish a week was linked to an 8% reduced risk for both fatal and non-fatal cardiovascular disease. The rich potassium content of salmon may make it beneficial for heart disease, as well. Coconut water Coconut water has become a popular health drink. It's sweet and nutty, low in sugar, and high in electrolytes. The body needs electrolytes to help balance its pH and maintain proper nerve, heart, and muscle function and hydration. One of these electrolytes is potassium. Drinking 1 cup (240 grams) of coconut water will provide 600 mg of potassium. Coconut water's high electrolyte content makes it an excellent drink for rehydrating after challenging physical activities.
